Da gusto leer alguna reseña positiva, por pequeña que sea.
http://www.insidermonkey.com/blog/three-noteworthy-analyst-calls-on-wednesday-research-in-motion-ltd-bbry-kohls-corporation-kss-69313/
- Analyst Provides a Major Vote of Confidence for this Small Biotech -
It has been a volatile year for Threshold Pharmaceuticals, and on Wednesday the stock rallied 11% following a major upgrade and a price target of more than 100% its current price. Over the last 14 months, all eyes have been on the company’s lead product, a late phase product called TH-302, which is used to treat cancers.
Last year a partnership with Merck KGaA(ADR) (PINK:MKGAY) and a 63% upside in progression-free survival helped Threshold become one of the best performing stocks in the market. However, Piper Jaffray took a deeper look at the product, and the company, and is now saying that TH-302 is superior to rivals when used for soft-tissue sarcoma. The analyst believes the company’s hypoxia-activation platform will be able to be used to treat a wide array of cancers, not just one or two, and sees massive potential down the road.
This upgrade served as reassurance to the investment community, as the stock broke above its $4.50 resistance. Now, the stock is facing resistance at $5.10, but if it can surpass this level then I’d look to buy at these levels.
